Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Seizert Capital Partners LLC

Seizert Capital Partners LLC reduced its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 10.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 377,528 shares of the biotechnology company’s stock after selling 42,107 shares during the quarter. Seizert Capital Partners LLC owned approximately 0.14% of Exelixis worth $13,938,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Exelixis by 32.2% during the 1st quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 1,328 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Exelixis during the 4th quarter worth about $17,046,000. Wells Fargo & Company MN boosted its position in shares of Exelixis by 1,637.9% during the 4th quarter. Wells Fargo & Company MN now owns 746,286 shares of the biotechnology company’s stock worth $24,851,000 after acquiring an additional 703,343 shares in the last quarter. Park Avenue Securities LLC boosted its position in shares of Exelixis by 10.6% during the 1st quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock worth $272,000 after acquiring an additional 707 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Exelixis by 23.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock worth $9,159,000 after acquiring an additional 47,845 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Tuesday. Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a report on Thursday, April 17th. Citigroup boosted their target price on Exelixis from $45.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, May 15th. Barclays boosted their target price on Exelixis from $29.00 to $40.00 and gave the company an “equal weight” rating in a report on Thursday, July 10th. Finally, Royal Bank Of Canada reduced their target price on Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and an average price target of $44.72.

Exelixis Trading Down 16.8%

Shares of EXEL stock opened at $36.94 on Wednesday. The company has a market cap of $10.07 billion, a price-to-earnings ratio of 17.76, a price-to-earnings-growth ratio of 0.88 and a beta of 0.28. The stock has a 50 day simple moving average of $43.30 and a 200-day simple moving average of $38.90. Exelixis, Inc. has a 12-month low of $23.00 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a return on equity of 26.90% and a net margin of 27.01%. The company’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.84 EPS. On average, equities analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, Director Stelios Papadopoulos sold 36,508 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $44.35, for a total transaction of $1,619,129.80. Following the completion of the transaction, the director directly owned 1,279,416 shares of the company’s stock, valued at approximately $56,742,099.60. This represents a 2.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Amy C. Peterson sold 72,776 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $45.47, for a total value of $3,309,124.72. Following the transaction, the chief marketing officer directly owned 465,393 shares of the company’s stock, valued at approximately $21,161,419.71. This trade represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 458,113 shares of company stock worth $21,024,817. 2.85% of the stock is currently owned by company insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.